These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
187 related articles for article (PubMed ID: 32017530)
1. Unraveling the Role of Receptor for Advanced Glycation End Products (RAGE) and Its Ligands in Myasthenia Gravis. Angelopoulou E; Paudel YN; Piperi C ACS Chem Neurosci; 2020 Mar; 11(5):663-673. PubMed ID: 32017530 [TBL] [Abstract][Full Text] [Related]
2. The receptor for advanced glycation endproducts and its ligands in patients with myasthenia gravis. Moser B; Bekos C; Zimprich F; Nickl S; Klepetko W; Ankersmit J Biochem Biophys Res Commun; 2012 Mar; 420(1):96-101. PubMed ID: 22405771 [TBL] [Abstract][Full Text] [Related]
3. Activation of the receptor for advanced glycation end products (RAGE) exacerbates experimental autoimmune myasthenia gravis symptoms. Mu L; Zhang Y; Sun B; Wang J; Xie X; Li N; Zhang J; Kong Q; Liu Y; Han Z; Wang G; Fu Z; Yu B; Li G; Li H Clin Immunol; 2011 Oct; 141(1):36-48. PubMed ID: 21570918 [TBL] [Abstract][Full Text] [Related]
4. Recombinant Acetylcholine Receptor Immunization Induces a Robust Model of Experimental Autoimmune Myasthenia Gravis in Mice. Theissen L; Schroeter CB; Huntemann N; Räuber S; Dobelmann V; Cengiz D; Herrmann A; Koch-Hölsken K; Gerdes N; Hu H; Mourikis P; Polzin A; Kelm M; Hartung HP; Meuth SG; Nelke C; Ruck T Cells; 2024 Mar; 13(6):. PubMed ID: 38534352 [TBL] [Abstract][Full Text] [Related]
5. Pathological mechanisms in experimental autoimmune myasthenia gravis. II. Passive transfer of experimental autoimmune myasthenia gravis in rats with anti-acetylcholine recepotr antibodies. Lindstrom JM; Engel AG; Seybold ME; Lennon VA; Lambert EH J Exp Med; 1976 Sep; 144(3):739-53. PubMed ID: 182897 [TBL] [Abstract][Full Text] [Related]
12. Acetylcholine receptor-specific immunosuppressive therapy of experimental autoimmune myasthenia gravis and myasthenia gravis. Luo J; Lindstrom J Ann N Y Acad Sci; 2018 Feb; 1413(1):76-81. PubMed ID: 29377167 [TBL] [Abstract][Full Text] [Related]
13. Myasthenia gravis: the role of complement at the neuromuscular junction. Howard JF Ann N Y Acad Sci; 2018 Jan; 1412(1):113-128. PubMed ID: 29266249 [TBL] [Abstract][Full Text] [Related]
14. ATRA alters humoral responses associated with amelioration of EAMG symptoms by balancing Tfh/Tfr helper cell profiles. Xie X; Mu L; Yao X; Li N; Sun B; Li Y; Zhan X; Wang X; Kang X; Wang J; Liu Y; Zhang Y; Wang G; Wang D; Liu X; Kong Q; Li H Clin Immunol; 2013 Aug; 148(2):162-76. PubMed ID: 23773919 [TBL] [Abstract][Full Text] [Related]
15. Novel complement inhibitor limits severity of experimentally myasthenia gravis. Soltys J; Kusner LL; Young A; Richmonds C; Hatala D; Gong B; Shanmugavel V; Kaminski HJ Ann Neurol; 2009 Jan; 65(1):67-75. PubMed ID: 19194881 [TBL] [Abstract][Full Text] [Related]
16. Standardization of the experimental autoimmune myasthenia gravis (EAMG) model by immunization of rats with Torpedo californica acetylcholine receptors--Recommendations for methods and experimental designs. Losen M; Martinez-Martinez P; Molenaar PC; Lazaridis K; Tzartos S; Brenner T; Duan RS; Luo J; Lindstrom J; Kusner L Exp Neurol; 2015 Aug; 270():18-28. PubMed ID: 25796590 [TBL] [Abstract][Full Text] [Related]
17. Myasthenia Gravis: Pathogenic Effects of Autoantibodies on Neuromuscular Architecture. Koneczny I; Herbst R Cells; 2019 Jul; 8(7):. PubMed ID: 31269763 [TBL] [Abstract][Full Text] [Related]